louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03212820: Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla.(Group B ) A Randomized Controlled Clinical Trial
Official title: Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bone Resorption
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-07-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 20 patients were selected requiring implant placement and divided randomly into two groups (10 in each group)

* for the study group, starter drill is used to locate the point of insertion as planned then pilot drill is also used to the full desired working length after that all other sequential drills are used at a low speed (50-70 rpm) without irrigation .
* In the study group: implant will be inserted in the low speed osteotomy site.
* In the control group: implants will be inserted in the conventional prepared osteotomy site.
* For both groups there is no surgical guide used.
* The flap will then be copiously irrigated with saline in preparation for closure.
* The flap will then be closed using interrupted 4/0 resorbable sutures.


Eligibility criteria: Inclusion Criteria:

* Patients restoring missing maxillary teeth with implant placement.
* Both sexes.
* Age: 25-45
* Mesio-distal dimensions: Not less than 6 mm
* Bone Height: Not less than 12 mm
* Bucco-lingual dimensions: Not less than 8mm
* All measures will be assessed using CBCT.

Exclusion Criteria:

* Sites needing bone grafting or augmentation.
* Heavy smokers more than 20 cigarettes per day.
* Patients with systemic disease that may affect normal healing.

Primary outcomes:
measure: crestal bone loss
timeFrame: 6 month
Secondary outcomes:
measure: patient morbidity after procedure
timeFrame: 1 day
measure: Implant stability value
timeFrame: 3 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01112020: Components of Chlorhexidine Gluconate Dressing
Official title: Components & Tolerability of Chlorhexidine Gluconate Dressing Patch Compared to BioPatch & Tegaderm Chlorhexidine Gluconate Securement Dressing After Application to Healthy Subjects Over a 7-day Period
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Chlorhexidine digluconate (CHG)
Biopatch Protective Disk
Tegaderm CHG IV (intravenous) Securement Dressing
parachloroaniline (PCA)
No condition being studied.
Assessing components of CHG-containing dressings after use.
Lead sponsor: CareFusion
Sponsor class: INDUSTRY
First posted: 2010-04-28
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to determine the contents of a chlorhexidine-containing dressing after use.

Detailed description: To characterize the chemical composition of the CHG (2% CHG) Catheter Dressing Patch as compared to Biopatch Protective Disk with CHG, and Tegaderm IV (intravenous) Securement Dressing over a wear period of 7 days.

Eligibility criteria: Inclusion Criteria:

* Able to read, review and sign the Informed Consent
* Willing to shower using the same soap/cleansers from the Screening Visit through the end of the study
* Use study-approved contraceptive methods

Exclusion Criteria:

* Participation in an investigational study within 28 days prior to dosing.
* Clinically significant illness within 28 days prior to dosing.
* History of allergic responses to chlorhexidine, chlorhexidine-containing products, glycerol, adhesives, latex
* History of clinically significant skin disorders
* History of Type I diabetes mellitus, insulin-dependent diabetes mellitus(IDDM)
* History of significant dermatologic cancers (melanoma, squamous)
* Known history of immunologic disorders
* Use immunosuppressive or other proscribed medications
* Use of skin products at the application site
* Significant history of allergies to soaps, lotions, emollients, ointments, creams
* History of drug or alcohol addiction within the past year
* Pregnant, lactating, breast-feeding, or intends to become pregnant during the course of the study

Primary outcomes:
measure: Chlorhexidine gluconate (CHG) level
timeFrame: 1 week
Secondary outcomes:
measure: Parachloroaniline (PCA) level
timeFrame: 7 days
Other outcomes:
Locations:
city: St. Charles
country: United States
facility: Cetero Research
state: Missouri
Study officials:
affiliation: Cetero Research, San Antonio
name: Ramon Vargas, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01398020: Comparing 2L Bi-Pegyte to 4L PegLyte Regiments for Outpatient Colonic Preparation
Official title: Oral 2L Bi-PegLyte Versus 4L PegLyte Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Efficacy of Bowel Preparation
Ease of Bowel Preparation and Patient Tolerability
Keywords: Bowel Preparation
Patient comfort
Bi-Peglyte
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2011-07-20
Enrollment: 318
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The investigators wish to compare the efficacy and patient tolerability of a preparation consisting of 2L Bi-Peglyte plus 15mg of bisacodyl vs the standard preparation of 4L Peglyte. The investigators hypothesize that 2L Bi-Peglyte with 15mg bisacodyl will show higher efficacy and tolerability.


Eligibility criteria: Inclusion Criteria:

* Age 19 or older
* Outpatient colonoscopy

Exclusion Criteria:

* constipation

Primary outcomes:
measure: Difference in Boston Bowel Preparation Scale between the two groups
timeFrame: 30 minutes
Secondary outcomes:
measure: Difference in the number of participants who develop distress symptoms from bowel prep (and the type) between the two groups
timeFrame: 20 hours
measure: Difference in the absolute number/percentage of participants in the two groups who find the bowel prep experience easy, acceptable, difficult, very difficult, or unable to complete.
timeFrame: 20
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: St. Paul's Hospital
state: British Columbia
Study officials:
affiliation: The University of British Columbia
name: Robert A Enns, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01550120: Free Fatty Acids: Threshold Repeatability Study
Official title: Free Fatty Acids: Threshold Repeatability Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Taste, Non-esterified Fatty Acids
Keywords: taste
fat
threshold
sensitivity
human
Lead sponsor: Purdue University
Sponsor class: OTHER
First posted: 2012-03-09
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants between the ages of 18 and 55 years of age from any ethnic background who are in good health and are available for the next three months will be recruited. Additionally, equal numbers of lean and overweight participants will be sought.

Brief summary: This study seeks to determine if non-esterified fatty acid (NEFA) taste detection thresholds change with repeated testing. Threshold testing for NEFA taste has been reported by a number of laboratories, including our own; however, these studies have reported data for only one testing occasion. The investigators seek to conduct repeated testing to measure the test-retest reliability of these methods. The investigators believe that with repeated exposure to NEFA, a person's sensitivity increases. The investigators are also testing the efficiency of testing by two methods (forced-choice ascending trial versus staircase). Additionally, the association between taste responses, diet and BMI will be explored.


Eligibility criteria: Inclusion Criteria:

* 18-55 years old
* in good health
* available for three months

Exclusion Criteria:

Primary outcomes:
measure: Non-esterified fatty acid detection thresholds in humans
timeFrame: 6 months
measure: BMI
timeFrame: Baseline
Secondary outcomes:
measure: Habitual fat intake
timeFrame: Baseline
measure: testing method
timeFrame: 6 months
measure: hunger
timeFrame: each visit
Other outcomes:
Locations:
city: West Lafayette
country: United States
facility: Purdue University
state: Indiana
Study officials:
affiliation: Purdue University
name: Richard D Mattes, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04891120: Treadmill Stress Test With and Without Mask
Official title: Treadmill Stress Test With and Without Mask: Comparison of Exercise Capacity and Perception
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Treadmill
Bruce
COVID-19
Mask
Healthy
Adults
METS
Metabolic equivalent
Borg
Exercise
Stress test
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
First posted: 2021-05-18
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess if wearing a surgical mask affects the results of a standard treadmill test.

Detailed description: The persons interested to participate will be informed of the implication and potential risks associated with the study. The participants that accept and meet the eligibility criteria will give written consent and be randomized into two groups. One group will first perform a treadmill test with a surgical mask and then repeat the test without a mask. The second group will do the first treadmill test without a mask and the second one with a surgical mask.

Eligibility criteria: Inclusion Criteria:

* Adults (18-65 years old)
* Healthy
* Vaccinated against COVID-19

Exclusion Criteria:

* Any cardiac or respiratory condition
* Walking difficulty
* Waiting for a stress test for a medical reason
* Abnormal resting ECG
* Inability to wear a mask
* Inability to understand or follow the instructions
* Medical contraindication to performing a treadmill stress test

Primary outcomes:
measure: Change in Metabolic Equivalents With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
Secondary outcomes:
measure: Change in Borg's Category-Ratio Scale for Rating of Perceived Exertion With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
Other outcomes:
measure: Change in Exercise Duration With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
measure: Change in Heart Rate During Exercise With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
measure: Change in Blood Pressure During Exercise With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
measure: Change in Oxygen Saturation During Exercise With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
measure: Change in Duration of Exercise Before Reaching 85% of Predicted Maximal Heart Rate With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
measure: Change in Calculated Maximal Oxygen Consumption During Exercise With vs Without a Mask
timeFrame: Through study completion, an average of 1 week
Locations:
city: Sherbrooke
country: Canada
facility: Centre Hospitalier Universitaire de Sherbrooke
state: Quebec
Study officials:
affiliation: Université de Sherbrooke
name: Warner Mampuya, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00823420: Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential
Official title: Influence of a Prematuration Culture With a PDE3-I on Embryonic Aneuploidy Rate and Developmental Potential
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Infertility
Keywords: PCOS and normal ovulatory patients
aneuploidy
in-vitro maturation of oocytes
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: University of Adelaide
name: Cook Group Incorporated
First posted: 2009-01-15
Enrollment: 213
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: A single centre randomised controlled trial investigating the influence of a novel prematuration system (PMS) using a phosphodiesterase-3 inhibitor for in-vitro maturation of oocytes


Eligibility criteria: Inclusion Criteria:

* healthy volunteers, either with PCOS/PCOS-like ovaries, or with normal ovaries, who undergo oocyte donation for research
* AFC at least 10
* AMH: \> 5 μg/L
* Female age \< 36 years

Exclusion Criteria:

* major uterine or ovarian abnormalities

Primary outcomes:
measure: Incidence of aneuploidy rate by fluorescence in situ hybridisation (FISH) technique in 6 to 8 cell embryos from prolonged (PMC) IVM compared to conventional IVM on sibling oocytes.
timeFrame: 3 days after egg retrieval
Secondary outcomes:
measure: Implantation potential of embryos from conventional IVM performed on Type II COC. Efficiency of both maturation systems in obtaining blastocysts. Endometrium quality in IVM cycles.
timeFrame: 7 days after egg retrieval
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Centre for Reproductive Medicine
Study officials:
References:
Clinical trial NCT03442920: Evaluation of Periodontal Diseases and Obesity in Women
Official title: The Effects of Obesity and Periodontitis on Biochemical Parameters in Women Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontal Diseases
Obesity
Keywords: obesity
periodontal diseases
gingival crevicular fluid
saliva
serum
Lead sponsor: Kocaeli University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2018-02-22
Enrollment: 71
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study was to evaluate the effect of obesity and exercise on periodontal and biochemical parameters \[serum, saliva and gingival crevicular fluid (GCF) adipokines (interleukin-1β, tumor necrosis factor-α, leptin, resistin and adiponectin)\].

Detailed description: It is thought that adipokines may play a role on periodontal disease in obese subjects, periodontal disease may also aggravate the existing systemic disease by changing the inflammatory parameters in the body. The aim of this study was to evaluate the effect of obesity and exercise on periodontal and biochemical parameters \[serum, saliva and gingival crevicular fluid (GCF) adipokines (interleukin-1β, tumor necrosis factor-α, leptin, resistin and adiponectin)\].

Eligibility criteria: Inclusion Criteria:

* Being women,
* Older than 18 yrs old,
* Not being pregnant,
* Not being disabled,
* For study group; being obese, not for healthy group being systemically health and in normal weight
* Not treated periodontological in the last 6 months

Exclusion Criteria:

* Younger than 18 yrs old,
* Smokers who smokes more than 10 cigarettes in a day,
* Uncontrolled systemic diseases,
* Having periodontal treatment
* who needs antibiotic prophylaxis

Primary outcomes:
measure: Biochemical variables GCF
timeFrame: 12 week
measure: Biochemical variables GCF
timeFrame: 12 week
Secondary outcomes:
measure: Biochemical variables_Saliva
timeFrame: 12 week
measure: Biochemical variables_Saliva
timeFrame: 12 week
measure: Biochemical variables_Serum
timeFrame: 12 week
measure: Biochemical variables_Serum
timeFrame: 12 week
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University
Study officials:
References:
Clinical trial NCT03385174: Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain's Vessels and Blood Flow
Official title: Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain's Vessels and Blood Flow
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Headache Disorders
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2017-12-28
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Studying Carbon monoxide effects on brain vessels in healthy volunteers with magnetic resonance imaging.

Detailed description: In this study we will systematically investigate the headache-releasing properties of carbon monoxide as well as measure the effect of carbon monoxide on mean blood flow rate in the brain's large vessel with magnetic resonance imaging. These studies are important for understanding and further investigating the carbon monoxide's headache-releasing effect in healthy subjects.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* Aged 18-50
* 50-100 kg

Exclusion Criteria:

* Tension type headache more than 5 dage /month
* Other primary headaches
* Daily medication except contraceptives
* Drug taken within 4 times the halflife for the specific drug except contraceptives
* Pregnant or lactating women
* Exposure to radiation within the last year
* Headache within the last 24 hours before start of trial
* Hypertension
* Hypotension
* Respiratory or cardiac disease
* Smoking
* Primary relatives with current or previous migraine

Primary outcomes:
measure: Changes in brain blood vessels diameters after a short CO inhalation
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
Study officials:
References:
Clinical trial NCT04690374: Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor
Official title: Registry for Patients With Desmoplastic Small Round Cell Tumor
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Desmoplastic Small Round Cell Tumor
Keywords: Patient registry
20-551
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2020-12-30
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study is a registry protocol for patients with DSRCT.

Brief summary: This study is a patient registry of people with Desmoplastic Small Round Cell Tumor (DSRCT). A patient registry is a collection of health information about a group of people, and it is usually focused on a specific diagnosis or disease.

The purpose of this registry is to create a database- a collection of information-or better understanding DSRCT. Researchers will use the information from this database to learn more about DSRCT and for current and future research on DSRCT.


Eligibility criteria: Inclusion Criteria:

* Participants must have a diagnosis of desmoplastic small round cell tumor
* Participants may be of any age as long as the appropriate consent and assent may be obtained
* Willing to provide historical and longitudinal clinical data

Exclusion Criteria:

* Participant unwilling to provide consent or share historical and longitudinal clinical data

Primary outcomes:
measure: Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor
timeFrame: 7 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Emily Slotkin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01203774: Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
Official title: "Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients Discharged From the Hospital"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes
Keywords: Diabetes
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: Sanofi
First posted: 2010-09-16
Enrollment: 43
Sex: ALL
Minimum age (years): 22
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control, compliance, and patient satisfaction and preference. The investigators will test this hypothesis in a randomized, crossover trial.


Eligibility criteria: Inclusion Criteria:

* All patients with type 1 and 2 diabetes discharged from the hospital with recommendations to take Glargine

Exclusion Criteria:

* Patients unwilling to participate and patients incapable of complying with the study regimen, such as patients with alcohol and drug addiction problems and patients with severe mental illness

Primary outcomes:
measure: HbA1c at Three Months of Each Period of Treatment
timeFrame: Baseline, Month 3 (End of Intervention 1), Month 6 (End of intervention 2)
Secondary outcomes:
measure: Compliance and Patient Satisfaction
timeFrame: 6 months of treatment after discharge from the hospital
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Denver
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Boris Draznin, M.D.
role: PRINCIPAL_INVESTIGATOR
References: